Source: Amicus Therapeutics, Inc.
CRANBURY, N.J., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq:FOLD) today announced the appointment of Michael C. Diem, MD as Senior Vice President of Business and Corporate Development. He will be responsible for leading all business and corporate development activities. Dr. Diem will be a key member of the Amicus senior leadership team reporting to John F. Crowley, Chairman and Chief Executive Officer of Amicus.
Dr. Diem is a driven business executive and physician with 12 years of global experience in the pharmaceutical and biotechnology industries, including leadership roles in corporate and business development at AstraZeneca and GlaxoSmithKline (GSK) Rare Diseases. He also has more than nine years of experience in academic and clinical medicine.
“I am pleased to welcome Dr. Mike Diem to our senior leadership team at Amicus,” stated Mr. Crowley. “Mike has an outstanding track record in global business development and corporate strategy within the biotechnology and pharmaceutical industries. Mike will be a key leader for Amicus as we evaluate strategies to enhance our portfolio of leading edge rare disease medicines and technologies. He will be extremely valuable to Amicus as we continue to build a top global biotechnology company focused on devastating rare diseases.”
Prior to joining Amicus, Dr. Diem was Senior Vice President of Corporate and Business Development at Aevi Genomic Medicine, where he led all business development and licensing activities. Previously, Dr. Diem was the Global Head of Corporate Strategy and Corporate Development for AstraZeneca, where he was responsible for mergers and acquisitions, externalization opportunities and divestitures, global opportunities in new areas of business and the company’s strategic investment activities (including MedImmune Ventures). Prior to joining AstraZeneca, Dr. Diem was the Head of Business Development for GSK Rare Diseases where he led the partnerships, licensing and mergers and acquisitions activities that formed the Company’s rare disease portfolio. Earlier he was a partner in GSK’s corporate venture capital firm, SR One, Limited and served on the boards of numerous companies. Prior to GSK, Mike was an associate at Frantz Medical Ventures and practiced medicine for six years.
“I am excited to join the Amicus team during such an important period of growth and globalization,” said Dr. Diem. “Amicus is well-positioned for further success with a novel rare disease portfolio as well as a deep commitment to delivering meaningful benefits for people living with rare diseases.”
Dr. Diem holds a BA in biological sciences from Rutgers University, an MD from the Rutgers-Robert Wood Johnson Medical School and an MBA from the Weatherhead School of Management at Case Western Reserve University. He completed his medical training at Duke University Medical Center and is an alumnus of the Kauffman Fellows Program. Mike is currently a board director at VenatoRx Pharmaceuticals and is a member of the board of governors of the Boys and Girls Clubs of Philadelphia.
About Amicus Therapeutics
Amicus Therapeutics (Nasdaq:FOLD) is a global biotechnology company at the forefront of therapies for rare and orphan diseases. The Company has a robust pipeline of advanced therapies for a broad range of human genetic diseases. Amicus’ lead programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, as well as novel enzyme replacement therapy (ERT) and biologic products for Fabry disease, Pompe disease, and other rare and devastating diseases.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, financing plans, and the projected cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA, may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results for any of our product candidates. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our previous filings with the SEC and in our Annual Report on Form 10-K for the year ended December 31, 2016 and Quarterly Report on 10-Q for the Quarter ended June 30, 2017. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof.
Sara Pellegrino, IRC
Senior Director, Investor Relations